SRC and neoplasm: Since Src had been demonstrated to contribute to tumours developing resistance to AR target therapy, a phase II trial was also designed to test 26 metastatic CRPC patients with no prior chemotherapy who received abiraterone plus prednisone together with placebo or dasatinib (118).